Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minoxidil sublingual dose-ranging extension study in male androgenetic alopecia
ACTRN12626000182392Phase 2Not yet recruiting
- Sponsor
- Sinclair Dermatology
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of minoxidil in androgenetic alopecia (AGA) (3 arms), sponsored by Sinclair Dermatology. Primary endpoint: Mean change in vertex scalp Target Area Hair Count. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
minoxidil
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on ACTRN12626000182392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000182392.